|Industry:||Nutrition supplement; protect from chronic pain and inflammation|
|Quantities:||1kg; 20kg; 25kg|
|INN (International Nonproprietary Name):|
|N-(2-Hydroxyethyl)hexadecanamide; PEA; Palmidrol|
|Palmitoylethanolamide; N-(2-Hydroxyethyl)hexadecanamide; PEA; Palmidrol|
|CAS Registry Number:|
Product name: Palmitoylethanolamide Other name: N-(2-Hydroxyethyl)hexadecanamide; PEA; PalmidrolCAS: 544-31-0Formula: C18H37NO2Mol. Mass: 299.49Appearance: white crystalline powderAssay: 98%Packing: 25kg/drum Palmitoylethanolamide (PEA) is an endogenous fatty acid amide, belonging to the class of nuclear factor agonists. PEA has been demonstrated to bind to a receptor in the cell-nucleus (a nuclear receptor) and exerts a great variety of biological functions related to chronic pain and inflammation. The main target is thought to be the peroxisome proliferator-activated receptor alpha (PPAR-?). PEA also has affinity to cannabinoid-like G-coupled receptorsGPR55 and GPR119. PEA cannot strictly be considered a classic endocannabinoid because it lacks affinity for the cannabinoid receptors CB1 and CB2. However, the presence of PEA (and other structurally related N-acylethanolamines) has been known to enhance anandamide activity by a so-called "entourage effect".Several papers have demonstrated that an imbalance of the endocannabinoid system (ECS) and alterations in the levels of PEA occur in acute and chronic inflammation. For instance during ?-amyloid-induced neuroinflammation the deregulation of cannabinoid receptors and its endogenous ligands accompanies the development and progression of disease. PEA has been shown to have anti-inflammatory, anti-nociceptive, neuroprotective, and anticonvulsant properties.
Return to overview